NCT05865054 Vascular MRI Evaluation in Giant Cell Arteritis (VEGA)
| NCT ID | NCT05865054 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pennsylvania |
| Condition | Giant Cell Arteritis |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2020-07-29 |
| Primary Completion | 2030-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2020-07-29 with a primary completion date of 2030-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The research study is being conducted to determine the utility of magnetic resonance imaging (MRI) in identifying inflammation of arteries supplying blood to the head, brain, and eyes. The target population includes patient with suspected giant cell arteritis (GCA; temporal arteritis).
Eligibility Criteria
Inclusion Criteria: * Age 50 years or older * First presentation of suspected GCA * New or worsening cranial manifestations within 4 weeks of enrollment concerning for active GCA * Elevated CRP greater than 1.0 mg/dl * Plan to undergo temporal artery biopsy or ultrasound for diagnosis Exclusion Criteria: * Contra-indication to receiving MRI including: Implanted medical devices, pacemaker, and metallic foreign fragments inside body/orbits Known gadolinium allergy Women who are pregnant or nursing * Absence of cranial symptoms related to GCA (e.g., only large vessel GCA)
Contact & Investigator
Rennie Rhee, MD
PRINCIPAL INVESTIGATOR
University of Pennsylvania
Frequently Asked Questions
Who can join the NCT05865054 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Giant Cell Arteritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05865054 currently recruiting?
Yes, NCT05865054 is actively recruiting participants. Contact the research team at Brenda_Hernandez-Romero@pennmedicine.upenn.edu for enrollment information.
Where is the NCT05865054 trial being conducted?
This trial is being conducted at Rochester, United States, Philadelphia, United States, Hamilton, Canada, Würzburg, Germany.
Who is sponsoring the NCT05865054 clinical trial?
NCT05865054 is sponsored by University of Pennsylvania. The principal investigator is Rennie Rhee, MD at University of Pennsylvania. The trial plans to enroll 400 participants.